Researcher

Gui Zhao is a Scientist at the A*STAR Bioprocessing Technology Institute. His research focuses on developing nanomedicine-based approaches for therapeutic delivery and immune modulation in vivo. He develops nanoparticle-based delivery systems, including polymeric nanoparticles and lipid nanoparticles (LNPs), to deliver different cargos, such as siRNA, mRNA, plasmid DNA and proteins, for applications in autoimmune diseases, cancer therapy and vaccination. These approaches enable the modulation and engineering of immune cells, tumour cells and tumour microenvironments. Currently, he is mainly working on PEG-free LNP development and LNP-based approaches for in vivo immune cell engineering.